Výsledky vyhledávání - "Irene Kuehrer"

Akademický článek

Discrimination between Circulating Endothelial Cells and Blood Cell Populations with Overlapping Phenotype Reveals Distinct Regulation and Predictive Potential in Cancer Therapy

Autor: Patrick Starlinger, Philipp Brugger, Christian Reiter, Dominic Schauer, Silvia Sommerfeldt, Dietmar Tamandl, Irene Kuehrer, Sebastian F. Schoppmann, Michael Gnant, Christine Brostjan

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 10, Pp 980-990 (2011)

BACKGROUND: Circulating endothelial cells (CECs) have been proposed to predict patient response to antiangiogenic cancer therapy. However, contradictory reports and inconsistency in the phenotypic identification of CECs have led us to compare three c

Externí odkaz: https://doaj.org/article/5ae5aa0b536f49a390d4620040170add

Zobrazit plný text záznamu

Akademický článek

Myelosuppression of Thrombocytes and Monocytes Is Associated with a Lack of Synergy between Chemotherapy and Anti-VEGF Treatment

Autor: Patrick Starlinger, Philipp Brugger, Dominic Schauer, Silvia Sommerfeldt, Dietmar Tamandl, Irene Kuehrer, Sebastian F. Schoppmann, Michael Gnant, Christine Brostjan

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 5, Pp 419-427 (2011)

Purpose: Chemotherapeutic agents that have shown improved patient outcome when combined with anti-vascular endothelial growth factor (VEGF) therapy were recently identified to induce the mobilization of proangiogenic Tie-2-expressing monocytes (TEMs)

Externí odkaz: https://doaj.org/article/5eb0c82df75a4458990a76808f330aef

Zobrazit plný text záznamu

655 Pivotal screening and proposed treatment algorithm for immune checkpoint inhibitor–induced cardio/myotoxicities in neoadjuvant-treated rectal cancer patients: experience from the CHINOREC trial

Autor: Johannes Laengle, Jutta Bergler-Klein, Simon Hametner, Ellen Gelpi, Irene Kuehrer, Branka Petricevic, Askin Kulu, Clemens Bittermann, Anton Stift, Friedrich Laengle, Klaus Machold, Stephan Blueml, Michael Bergmann

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::115938c104b31107c9f2f5ce248e1ba8
https://doi.org/10.1136/jitc-2022-sitc2022.0655

Zobrazit plný text záznamu

Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial

Publikováno v: Journal of Clinical Oncology. 39:TPS3623-TPS3623

TPS3623 Background: Immune checkpoint inhibitors (ICI), such as ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) or nivolumab (anti-programmed cell death protein 1) have been proven to be an effective strategy in solid cancers. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39247a2ac356ed2088d6e8bfa03b981d
https://doi.org/10.1200/jco.2021.39.15_suppl.tps3623

Zobrazit plný text záznamu

LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases

Autor: Gudrun Piringer, Friedrich Laengle, Judith Stift, Angelika Pichler, Wolfgang Eisterer, Thomas Gruenberger, Josef Thaler, Dietmar Oefner, Reinhold Fuegger, Arno Amann, Irene Kuehrer, Lidija Soelkner, Michael Gnant, Johannes Andel, Istvan Levente Viragos-Toth, Klaus Kaczirek

Publikováno v: Journal of Clinical Oncology. 38:e16046-e16046

e16046 Background: Nearly half of patients with colorectal cancer develop liver metastases and only 20% are initially resectable. Surgical resection of liver metastases results in five-year survival rates of 24-48%. Perioperative FOLFOX therapy incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c219ba94d25e88dcfdf11208c662292
https://doi.org/10.1200/jco.2020.38.15_suppl.e16046

Zobrazit plný text záznamu

NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer

Autor: Michael Gnant, Claus Koelblinger, Irene Kuehrer, Klaus Sahora, Martin Schindl, P. Goetzinger

Publikováno v: World Journal of Surgery. 35:1580-1589

About 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b6b5ed1e11bcafcebcf9d33f17284f
https://doi.org/10.1007/s00268-011-1113-8

Zobrazit plný text záznamu

NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer

Autor: Markus Peck-Radosavljevic, Irene Kuehrer, Ahmed Ba-Ssalamah, Axel Eisenhut, P. Goetzinger, Belgin Akan, Claus Koellblinger, Michael Gnant, Klaus Sahora, Raimund Jakesz, Christoph C. Zielinski, Bela Teleky

Publikováno v: Surgery. 149:311-320

Background Neoadjuvant chemotherapy can facilitate pancreatic resection in patients with initially unresectable pancreatic cancer (PC). We report the results of a phase II trial of gemcitabine-oxaliplatin neoadjuvant chemotherapy for patients with lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d0d5a57e1f2f6bf51ed571f03d6fbf
https://doi.org/10.1016/j.surg.2010.07.048

Zobrazit plný text záznamu

Thrombospondin‐1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes

Autor: Alice Assinger, Christine Brostjan, Herwig P. Moll, T. Gruenberger, Sebastian F. Schoppmann, Birgit Gruenberger, Patrick Starlinger, Konrad Hoetzenecker, Michael Gnant, C. Nemeth, Irene Kuehrer

Publikováno v: Journal of Thrombosis and Haemostasis. 8:1809-1819

Summary. Background: Measuring platelet activation in patients has become a potent method to investigate pathophysiological processes. However, the commonly applied markers are sensitive to detrimental influences by in vitro platelet activation durin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::370ac7a274c4b7536eb65b41800ca9f0
https://doi.org/10.1111/j.1538-7836.2010.03908.x

Zobrazit plný text záznamu

A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer

Autor: Klaus, Sahora, Martin, Schindl, Irene, Kuehrer, Axel, Eisenhut, Gregor, Werba, Christine, Brostjan, Bela, Telek, Ahmed, Ba'ssalamah, Judith, Stift, Sebastian F, Schoppmann, Michael, Gnant

Publikováno v: Anticancer research. 34(5)

We report the results of a phase II trial of adding the anti-ascular endothelial growth factor (VEGF) bevacizumab to gemcitabine neoadjuvant chemotherapy for patients with borderline and unresectable non-metastatic pancreatic cancer.Patients were ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::46759e8c7a675672e1e64f93846d6409
https://pubmed.ncbi.nlm.nih.gov/24778046

Zobrazit plný text záznamu

Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression

Autor: Gabriela Kornek, Irene Kuehrer, Judith Stift, Thorsten Fuereder, Doris Hoeflmayer, Werner Scheithauer, Nadja Stranzl

Publikováno v: European journal of clinical investigation. 44(10)

Introduction There are no data about the efficacy of gemcitabine in combination with oxaliplatin (GEMOX) and erlotinib for the treatment of metastatic pancreatic cancer (mPC). Thus, we performed this retrospective analysis in mPC patients to investig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f0f1f2bcecc9d487a5dd3677ecb8ce
https://pubmed.ncbi.nlm.nih.gov/25145842

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání